EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Exploring the Side Effects of GLP-1 Receptor Agonist: To Ensure Its Optimal Positioning

Jung A Kim, Hye Jin Yoo

Diabetes & Metabolism Journal · 01.07.2025 · 49 (4) · 525-541

DOI: 10.4093/dmj.2025.0242 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Diabetes & Metabolism Journal, erschienen am 01.07.2025. Verfasst von Jung A Kim und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Endocrinology and Metabolism, Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea. Hauptthemen laut MEDLINE: Glucagon-Like Peptide-1 Receptor Agonists, Hypoglycemic Agents, Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 81-mal zitiert (Crossref) und nennt 114 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Research Foundation of Korea, Ministry of Education.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Although glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have demonstrated considerable efficacy in the treatment of diabetes and obesity, it is essential to recognize that their use is associated with certain intrinsic risks that must not be disregarded. The incidence of adverse effects, particularly gastrointestinal complications, psychiatric disorders, and ocular problems, highlights the critical need for thorough patient assessment and continuous monitoring to ensure both the safety and effectiveness of treatment. Despite the possibility of adverse events, GLP-1 RAs continue to represent a crucial therapeutic modality for metabolic disturbances. This highlights the significance of ongoing research initiatives aimed at optimizing their safe utilization and refining current treatment protocols to improve patient outcomes. This review summarizes updated research findings regarding the adverse effects of GLP-1 RAs, their mechanisms of action, and guidelines for clinical application.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glucagon-Like Peptide-1 Receptor AgonistsHypoglycemic AgentsDiabetes Mellitus, Type 2HumansGlucagon-Like Peptide-1 ReceptorGastrointestinal DiseasesObesity

Stichwörter der Autor:innen

Biliary tract diseasesDrug-related side effects and adverse reactionsEye diseasesGastrointestinal diseasesGlucagon-like peptide-1 receptor agonistsMental disordersPancreatic diseases

Substanzen

Glucagon-Like Peptide-1 Receptor AgonistsHypoglycemic AgentsGlucagon-Like Peptide-1 Receptor

Autor:innen und Institutionen

  • Division of Endocrinology and Metabolism, Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea.

Förderung

  • National Research Foundation of Korea
  • Ministry of Education

Zitieren

APA

Kim, J. A., & Yoo, H. J. (2025). Exploring the Side Effects of GLP-1 Receptor Agonist: To Ensure Its Optimal Positioning. Diabetes & Metabolism Journal, 49(4), 525-541. https://doi.org/10.4093/dmj.2025.0242

Vancouver

Kim JA, Yoo HJ. Exploring the Side Effects of GLP-1 Receptor Agonist: To Ensure Its Optimal Positioning. Diabetes & Metabolism Journal. 2025;49(4):525-541. doi:10.4093/dmj.2025.0242

BibTeX
@article{Kim2025,
  author = {Kim, Jung A and Yoo, Hye Jin},
  title = {Exploring the Side Effects of GLP-1 Receptor Agonist: To Ensure Its Optimal Positioning},
  journal = {Diabetes & Metabolism Journal},
  year = {2025},
  volume = {49},
  number = {4},
  pages = {525--541},
  doi = {10.4093/dmj.2025.0242}
}
Kostenlos starten →